Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody targeting CLEC12A on myeloid cells and CD3 on cytotoxic T cells. As a myeloid differentiation antigen, CLEC12A allows the compound to eliminate AML leukemia progenitor and stem cells through T cell-mediated proliferative lysis, making it valuable in acute myeloid leukemia (AML) research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Tepoditamab (MCLA-117) is a bispecific monoclonal antibody targeting CLEC12A on myeloid cells and CD3 on cytotoxic T cells. As a myeloid differentiation antigen, CLEC12A allows the compound to eliminate AML leukemia progenitor and stem cells through T cell-mediated proliferative lysis, making it valuable in acute myeloid leukemia (AML) research [1]. |
Cas No. | 2044679-53-8 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.